Antineutrophil cytoplasmic antibodies in patients with Graves’ disease: association of antimyeloperoxidase autoantibodies with propylthiouracil therapy

References

• Gross WL, Schmitt WH, Csernok E. ANCA and associated dis-eases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 1993;91:1–12.
   Google Scholar
• Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994;46:1–15.
   Google Scholar
• Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512–23.
   PubMed Web of Science ®Google Scholar
• Stankus SJ, Johnson NT. Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure. Chest 1992;102:1595–6.
   PubMed Web of Science ®Google Scholar
• Dolman KM, Gans ROB, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342:651–2.
   PubMed Web of Science ®Google Scholar
• Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylth-iouracil in children. J Pediatr 1994;124:986–8.
   PubMed Web of Science ®Google Scholar
• Tanemoto M, Miyakawa H, Hanai J, Yago M, Kitaoka M, Uchida S. Myeloperoxidase—antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves' disease: report of three adult cases. Am J Kidney Dis 1995;26:774–80.
   PubMed Web of Science ®Google Scholar
• D'Cruz D, Chesser AMS, Lightowler C, Comer M, Hurst MJ, Baker LFtl, et al. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Ftheumatol 1995;34:1090–1.
   PubMedGoogle Scholar
• Romas E, Henderson DRF, Kirkham BW. Propylthiouracil therapy: an unusual cause of antineutrophil cytoplasmic antibody associated alveolar hemorrhage. J Ftheumatol 1995;22: 803.
   Google Scholar
• Gunton JE, Stiel J, Caterson RJ, McElduff A. Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endcrinol Metab 1999; 84:13–6.
   Google Scholar
• Kobayashi K, Shibata T, Sugisaki T. Aggravation of rat nephro-toxic serum nephritis by anti-myeloperoxidase antibodies. Kidney Int 1995;47:454–63.
   Google Scholar
• Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vas-culitis and idiopathic necrotizing and crescentic glomerulonephri-tis. N Engl J Med 1988;318:1651–7.
   PubMed Web of Science ®Google Scholar
• Shibata T, Berney T, Spertini F, Izui S. Rheumatoid factors in mice bearing the 1pr or gld mutation. Selective production of rheuma-toid factor cryoglobulins in MRLIMPJ-Ipillpr mice. Clin Exp Immunol 1992;87:190–5.
   Google Scholar
• Johnson DA, Gautsch JW, Sportsman JR, Elder JH. Improved technique utilizing nonfat dry milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gene Anal Tech 1984; 1:3–8.
   Google Scholar
• Olsen RL, Little C. Studies on the subunits of human myeloperoxidase. Biochem J 1984;222:701–9.
   PubMed Web of Science ®Google Scholar
• Andrews PC, Krinsky NI. The reductive cleavage of myeloperoxidase in half, producing enzymically active hemi-myeloperoxidase. J Biol Chem 1981;256:4211–8.
   PubMed Web of Science ®Google Scholar
• Andersen MR, Atkin CL, Eyre HJ. Intact form of myelo-peroxidase from normal human neutrophils. Arch Biochem Biophys 1982;214:273–83.
   Google Scholar
• Sera N, Ashizawa K, Ando T, Abe Y, Ide A, Usa T, et al. Treat-ment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000;10:595–9.
   PubMed Web of Science ®Google Scholar
• Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, et al. High prevalence of antineutrophil cytoplasmic antibody positiv-ity in childhood onset Graves' disease treated with propylthiou-racil. J Clin Endocrinol Metab 2000;85:4270–3.
   PubMed Web of Science ®Google Scholar
• Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000;142:587–90.
   Google Scholar
• Wada N, Mukai M, Kohno M, Notoya A, Ito T, Yoshioka N. Prevalence of serum anti-myeloperoxidase antineutrophil cyto-plasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 2002;49: 329–34.
   PubMed Web of Science ®Google Scholar
• Noh JY, Asari T, Hamada N, Makin° F, Ishikawa N, Abe Y, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves'-disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol 2001;54:651–4.
   Google Scholar
• Cooper DS. Antithyroid drugs. N Engl J Med 1984;311:1353–62.
   PubMed Web of Science ®Google Scholar
• Lam DCC, Lindsay RH. Accumulation of 2-[14q propylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol 1979;28:2289–96.
   PubMed Web of Science ®Google Scholar
• Lee E, Hirouchi M, Hosokawa M, Sayo H, Kohno M, Kariya K. Inactivation of peroxidases of rat bone marrow by repeated admin-istration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 1988;37:2151–3.
   PubMed Web of Science ®Google Scholar
• Lee E, Miki Y, Katsura H, Kariya K. Mechanism of inactivation of myeloperoxidase by propylthiouracil. Biochem Pharmacol 1990; 39:1467–71.
   PubMed Web of Science ®Google Scholar
• Wing SS, Fantus IG. Adverse immunologic effects of antithyroid drugs. Can Med Assoc J 1987;136:121–7.
   PubMed Web of Science ®Google Scholar
• Falk RJ, Becker M, Tervell R, Jennette JC. Anti-myeloperoxidase autoantibodies react with native but not denatured myeloper-oxidase. Clin Exp Immunol 1992;89:274–8.
   PubMed Web of Science ®Google Scholar
• Audrain MAP, Baranger TAR, Moguilevski N, Martin SJ, Devys A, Lockwood CM, et al. Anti-native and recombinant myelo-peroxidase monodonals and human autoantibodies. Clin Exp Immunol 1997;107:127–34.
   PubMed Web of Science ®Google Scholar
• Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115–9.
   PubMed Web of Science ®Google Scholar
• Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992;41:375–83.
   Google Scholar
• Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cul-tured endothelial cells. Am J Pathol 1992;141: 335–42.
   Google Scholar
• Jennette JC, Falk RJ. Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 1998;13 Suppl 1:16–20.
   PubMedGoogle Scholar
• Savage COS. ANCA-associated renal vasculitis. Kidney Int 2001; 60:1614–27.
   PubMed Web of Science ®Google Scholar